The Priority Review

Clinical trials Brief

Jade Biosciences registers Phase 3 study of JADE101 in IgA nephropathy

The study, titled the EVERGREEN STUDY, plans to enroll 480 participants and has a planned start date of December 2026. It will evaluate the safety and efficacy of JADE101 versus placebo in adults with immunoglobulin A nephropathy.

Primary source

ClinicalTrials.gov registry record, October 29, 2026

A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Read the source: A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation